Related Experiment Videos
Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.
Peter R Carroll1, J Kellogg Parsons1, Gerald Andriole1
1From UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Vanderbilt-Ingram Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Massachusetts General Hospital Cancer Center; The University of Texas MD Anderson Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Fox Chase Cancer Center; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; City of Hope Comprehensive Cancer Center; University of Washington/Seattle Cancer Care Alliance; Dana-Farber/Brigham and Women's Cancer Center; Huntsman Cancer Institute at the University of Utah; University of Colorado Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; Moffitt Cancer Center; Duke Cancer Institute; University of Alabama at Birmingham Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center; St. Jude Children's Research Hospital/University of Tennessee Health Science Center; and National Comprehensive Cancer Network.
The National Comprehensive Cancer Network (NCCN) updated its 2014 prostate cancer early detection guidelines. Recommendations now streamline testing ages and include new criteria for prostate cancer biopsies.
Area of Science:
- Urology
- Oncology
- Medical Guidelines
Background:
- The National Comprehensive Cancer Network (NCCN) provides guidelines for prostate cancer early detection.
- These guidelines assist men considering participation in prostate cancer screening programs.
- Recent updates aim to refine and simplify early detection recommendations.
Purpose of the Study:
- To highlight notable recent updates to the NCCN Prostate Cancer Early Detection Guidelines.
- To present a more streamlined and concise set of recommendations for prostate cancer screening.
- To inform clinicians and patients about updated criteria for prostate cancer testing and biopsy.
Main Methods:
- Review and analysis of the NCCN Prostate Cancer Early Detection Guidelines.
- Identification of key changes and updates in the 2014 version.
- Stratification of age ranges for initiating prostate cancer testing.
- Inclusion of new criteria for prostate biopsy indications.
Main Results:
- The 2014 NCCN guidelines offer a more streamlined approach to prostate cancer early detection.
- Age ranges for initiating prostate cancer testing have been stratified.
- Biopsy indications now incorporate both a specific cutpoint and the use of multiple risk variables.
- The Prostate Health Index is included as a biomarker to aid biopsy decisions in select men.
Conclusions:
- The updated NCCN guidelines provide a concise framework for prostate cancer early detection.
- New criteria enhance the decision-making process for prostate cancer testing and biopsy.
- Inclusion of biomarkers like the Prostate Health Index improves specificity in identifying men who need biopsy.